Benjamin Gregory Carlisle
Benjamin Gregory Carlisle
Verified email at - Homepage
Cited by
Cited by
Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials
B Carlisle, J Kimmelman, T Ramsay, N MacKinnon
Clinical Trials 12 (1), 77-83, 2015
Benefit, risk, and outcomes in drug development: a systematic review of sunitinib
B Carlisle, N Demko, G Freeman, A Hakala, N MacKinnon, T Ramsay, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
Rethinking Research Ethics: The Case of Postmarketing Trials
AJ London, J Kimmelman, B Carlisle
Science 336 (6081), 544-545, 2012
Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review
J Mattina, B Carlisle, Y Hachem, D Fergusson, J Kimmelman
PLoS biology 15 (2), 2017
Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials
A Hakala, J Kimmelman, B Carlisle, G Freeman, D Fergusson
Bmj 350, h1116, 2015
Proof of prespecified endpoints in medical research with the bitcoin blockchain
BG Carlisle
The Grey Literature [Internet] 25, 2014
Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval
B Carlisle, CA Federico, J Kimmelman
Bmj 360, k959, 2018
Drug development at the portfolio level is important for policy, care decisions and human protections
J Kimmelman, B Carlisle, M Gönen
Jama 318 (11), 1003-1004, 2017
Late, never or non‐existent: the inaccessibility of preclinical evidence for new drugs
CA Federico, B Carlisle, J Kimmelman, DA Fergusson
British journal of pharmacology 171 (18), 4247-4254, 2014
Numbat Meta-Analysis Extraction Manager
BG Carlisle
Studies of Ethics, Translation and Medicine (STREAM), Biomedical Ethics Unit …, 2015
Benefit, burden, and impact for a cohort of post-approval cancer combination trials
BG Carlisle, A Doussau, J Kimmelman
Clinical Trials, 1740774519873883, 2019
Recapping the recent plagiarism scandal
B Carlisle
Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study
BG Carlisle, A Doussau, J Kimmelman
BMJ open 10 (2), 2020
Non-existent identifiers in abstracts indexed by PubMed
BG Carlisle
medRxiv, 2020
Imatinib and the long tail of targeted drug development
BG Carlisle, T Zheng, J Kimmelman
Nature Reviews Clinical Oncology 17 (1), 1-3, 2020
How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?
M Pratte, S Ganeshamoorthy, B Carlisle, J Kimmelman
International journal of cancer 145 (12), 3370-3375, 2019
Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer
H Sarvas, B Carlisle, S Dolter, E Vinarov, J Kimmelman
JNCI: Journal of the National Cancer Institute, 2019
Cancer Precision Medicine Drug Development is Often Empirical: The Case of Imatinib, Dasatinib and Nilotinib
BG Carlisle, T Zheng, J Kimmelman
The moral efficiency of clinical trials in anti-cancer drug development, 53, 2019
The moral efficiency of clinical trials in anti-cancer drug development
BG Carlisle
McGill University, 2019
Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio
BG Carlisle, J Mattina, T Zheng, J Kimmelman
medRxiv, 19003467, 2019
The system can't perform the operation now. Try again later.
Articles 1–20